8,456 peer-reviewed studies, each with a short note written from its published abstract: what kind of study it was, who took part, what was measured and what the authors reported. Observational studies show associations, not proof.
People assigned to a diet, food or program and measured.
2020 / Double-blind, randomized, multicenter trial
A total of 13,078 statin-treated patients at high cardiovascular risk were randomized to receive 4 g/d of an omega-3 carboxylic acid formulation (EPA/DHA) or corn oil. The trial was prematurely halted for low probability of clinical benefit. The primary composite endpoint occurred in 12.0% of omega-3 CA patients versus 12.2% of corn oil patients (hazard ratio, 0.99 [95% CI, 0.90-1.09]; P = .84). A higher rate of gastrointestinal adverse events occurred in the omega-3 group (24.7%) compared to the corn oil group (14.7%).
Nicholls SJ, Lincoff AM, Garcia M, et al. JAMA, 2020. PMID 33190147
2020 / Randomized, double-blinded, placebo-controlled clinical trial
A 6-month trial examined the effects of vitamin D3, enhanced vitamin D2 in a mushroom matrix, standard mushroom, and placebo in 436 healthy adults aged ≥60 years. Total 25-OH-D and 25-OH-D3 levels were maintained in the vitamin D3 arm but decreased significantly (p < 0.05) in the other three arms. There were no significant effects of treatment on any measures of cognitive function or mood over 24 weeks.
Zajac IT, Barnes M, Cavuoto P, et al. Nutrients, 2020. PMID 33339304
2019 / Randomized controlled trial
Adults with self-reported depression were randomized to either a Mediterranean diet intervention (fortnightly food hampers, cooking workshops for 3 months, and fish oil for 6 months) or social groups fortnightly for 3 months. At 3 months, the MedDiet group showed a higher MedDiet score (t = 3.95, P < 0.01), greater reduction in depression (t = -2.24, P = 0.03), and improved mental health QoL (t = 2.10, P = 0.04), with benefits sustained at 6 months. Reduced depression correlated with higher MedDiet score (r = -0.298, P = 0.01), nuts (r = -0.264, P = 0.01), and vegetable diversity (r = -0.303, P = 0.01). Some correlations were also found between increased omega-3, decreased omega-6, and improved mental health.
Parletta N, Zarnowiecki D, Cho J, et al. Nutr Neurosci, 2019. PMID 29215971
2019 / Crossover trial
Researchers evaluated postprandial glucose and insulin responses to an oral glucose tolerance test (OGTT at 0800h vs 2000h, n=10) and a low GI meal consumed at 0800h, 2000h, and 0000h (n=9). In the OGTT, glucose iAUC was higher in the evening than morning (p=0.007). Following the low GI meal, glucose iAUC was higher at evening and midnight compared to morning (p=0.008, p=0.021), with no significant difference between evening and midnight (p=0.594). Insulin iAUC was also significantly higher at evening and midnight compared to morning (p=0.008 for both).
Leung GKW, Huggins CE, Bonham MP Clin Nutr, 2019. PMID 29248250
2019 / Randomized controlled trial
In a 4-week trial of 120 healthy adults, consuming 80 g/d or 120 g/d of prunes led to significantly greater increases in daily stool weight (+22.2 g/d and +32.8 g/d, respectively) versus control (-0.8 g/d, P = 0.026). Stool frequency was also significantly higher (P = 0.023), with increased Bifidobacteria across groups (P = 0.046) and increased flatulence. Prunes showed no effect on whole gut transit time, short-chain fatty acids, or stool pH.
Lever E, Scott SM, Louis P, et al. Clin Nutr, 2019. PMID 29398337
2019 / Randomized controlled trial
In 15 healthy women, brain responses to intragastric quinine-hydrochloride (10 µmol/kg) or placebo infusion were recorded using fMRI alongside appetite-related sensations, gastrointestinal hormones, and hedonic food intake. Quinine administration lowered octanoylated ghrelin (P<0.04), total ghrelin (P<0.01), and motilin (P<0.01) plasma levels, alongside lower prospective food consumption ratings (P<0.02) and hedonic food intake (P<0.05). Quinine also increased neural activity in the hypothalamus and hedonic brain regions but decreased activity in the homeostatic medulla (all pFWE-corrected<0.05).
Iven J, Biesiekierski JR, Zhao D, et al. Nutr Neurosci, 2019. PMID 29607741
2019 / Parallel randomized clinical trial
A parallel randomized clinical trial evaluated the effect of consuming 240 ml of soy milk daily as part of a 500-calorie deficit diet compared to the deficit diet alone for 8 weeks in 70 patients with NAFLD. The soy milk group showed significantly greater reductions in serum alanine aminotransferase (-12.06 ± 17.61 IU/L vs. -5 ± 8.58 IU/L, p = 0.04) and hs-CRP (-1.32 ± 1.60 mg/L vs. -0.36 ± 1.54 mg/L, p = 0.01). However, changes in fatty liver grade, other liver enzymes (AST, ALP, GGT), lipid profiles, and anthropometric indices did not differ significantly between groups.
Eslami O, Shidfar F, Maleki Z, et al. J Am Coll Nutr, 2019. PMID 30028245
2019 / Randomized open-label crossover trial
Fifteen patients with uncontrolled type 2 diabetes participated in a randomized, open-label crossover study receiving either two days of oatmeal or a diabetes-adapted diet during a 5-day hospital stay. Oatmeal significantly reduced required insulin doses on days 3 and 4 compared to day 2 (82.0±30.3 and 69.9±29.9 IU vs. 112±36.2 IU; P<0.001), whereas insulin requirements did not change during the control period. Mean blood glucose and fasting glucose changes did not differ significantly between treatments, but HbA1c was lower four weeks after the oatmeal intervention.
Delgado G, Kleber ME, Krämer BK, et al. Exp Clin Endocrinol Diabetes, 2019. PMID 30157531
2019 / Double-blind randomized controlled trial
In the double-blinded randomized controlled FLAX-PAD trial, PAD patients consumed a diet supplemented with either 30 g of milled flaxseed or placebo daily for 1 year. At baseline, cardiac arrhythmias were present in 48% of the flaxseed group and 32% of the placebo group. After 1 year, cardiac arrhythmias decreased by 2% in the flaxseed group and increased by 12% in the placebo group, which was not statistically significant (P > 0.05). Electrocardiographic variables did not change in either group, and improvements in initial and absolute claudication distances did not show a statistically significant intergroup difference.
Rodriguez-Leyva D, Rodriguez-Portelles A, Weighell W, et al. Can J Physiol Pharmacol, 2019. PMID 30308127
2019 / Matched controlled trial
Twenty-four resistance-trained males completed a lower-body resistance training session and were matched into cold water immersion (10 min at 10 °C), whole-body cryotherapy (3- and 4 min at -85 °C), or placebo groups. While whole-body cryotherapy attenuated soreness at 24 hours and positively influenced peak force at 48 hours compared to cold water immersion and placebo, many remaining outcomes were trivial, unclear, or favored placebo. Except for CRP at 24 hours, neither cryotherapy intervention reduced inflammatory responses compared to placebo.
Wilson LJ, Dimitriou L, Hills FA, et al. Eur J Appl Physiol, 2019. PMID 30310979
2019 / Randomized controlled trial
In a randomized trial, 150 patients with constipation-predominant irritable bowel syndrome consumed flixweed, fig, or control interventions for 4 months. Both flixweed and fig led to significant improvements in pain frequency, distention, defecation frequency, hard stool, quality of life, and bowel habit satisfaction compared to control. Neither intervention significantly altered C-reactive protein concentrations or the intensity of abdominal pain.
Pourmasoumi M, Ghiasvand R, Darvishi L, et al. Explore (NY), 2019. PMID 30318190
2019 / Randomised, double-blinded, placebo-controlled crossover trial
A randomized, double-blinded, placebo-controlled crossover trial evaluated the effects of 20 mg/day oral saffron versus placebo for 3 months each in 100 adults with mild/moderate age-related macular degeneration. Mean BCVA improved by 0.69 letters (p = 0.001) and mean-pooled mfERG latency decreased by 0.17 ms (p = 0.04) on saffron compared to placebo. In participants also taking AREDS supplements, mean BCVA improved by 0.73 letters (p = 0.006) and mfERG response density improved by 2.8% (p = 0.038). Adverse events did not differ significantly between groups (p > 0.10).
Broadhead GK, Grigg JR, McCluskey P, et al. Graefes Arch Clin Exp Ophthalmol, 2019. PMID 30343354
2019 / Clinical trial protocol
Researchers initiated a clinical trial protocol recruiting 5,000 subjects aged 45-65 to evaluate popular antiaging practices, including diet, drugs, supplements, and exercise. Participants provide blood samples to measure methylation age at the beginning, middle, and end of a 2-year period, with the primary endpoint being the difference in methylation age over 2 years. The exploratory study aims to detect whether certain combinations of strategies synergize to achieve age retardation of 25% or more.
Mitteldorf J Rejuvenation Res, 2019. PMID 30345885
2019 / Prospective crossover study
A prospective crossover study tracked real-time bowel movement data in 52 volunteers over 4 weeks (2 weeks without a defecation postural modification device [DPMD] followed by 2 weeks with DPMD). Across 1119 recorded bowel movements, utilizing the DPMD resulted in increased bowel emptiness (OR 3.64; 95% CI, 2.78-4.77) and reduced straining (OR 0.23; 95% CI, 0.18-0.30). Furthermore, not using the DPMD was associated with increased bowel movement duration (fold increase 1.25; 95% CI, 1.17-1.33).
Modi RM, Hinton A, Pinkhas D, et al. J Clin Gastroenterol, 2019. PMID 30346317
2019 / Multicenter, randomized, double-blind, placebo-controlled trial
A total of 8179 statin-treated patients with elevated triglycerides were randomized to receive 2 g of icosapent ethyl twice daily (4 g total) or placebo and followed for a median of 4.9 years. The primary composite endpoint occurred in 17.2% of the icosapent ethyl group versus 22.0% of the placebo group (HR, 0.75; 95% CI, 0.68 to 0.83; P<0.001), and cardiovascular death was lower (4.3% vs. 5.2%; HR, 0.80; 95% CI, 0.66 to 0.98; P=0.03). However, hospitalizations for atrial fibrillation or flutter were higher with icosapent ethyl (3.1% vs. 2.1%, P=0.004), and serious bleeding occurred in 2.7% versus 2.1% (P=0.06).
Bhatt DL, Steg PG, Miller M, et al. N Engl J Med, 2019. PMID 30415628
2019 / Randomized, placebo-controlled trial (two-by-two factorial)
A randomized, placebo-controlled trial tested vitamin D3 (2000 IU/day) versus placebo for the prevention of cancer and cardiovascular disease over a median follow-up of 5.3 years in 25,871 participants. Vitamin D was not associated with a lower risk of invasive cancer (HR 0.96; 95% CI, 0.88 to 1.06; P=0.47) or major cardiovascular events (HR 0.97; 95% CI, 0.85 to 1.12; P=0.69). Secondary endpoints, including death from cancer (HR 0.83; 95% CI, 0.67 to 1.02) and death from cardiovascular causes (HR 1.11; 95% CI, 0.88 to 1.40), also showed no significant differences, and no excess risks of hypercalcemia or other adverse events were identified.
Manson JE, Cook NR, Lee IM, et al. N Engl J Med, 2019. PMID 30415629
2019 / Randomized, placebo-controlled, 2x2 factorial trial
In the VITAL trial, 25,871 participants were randomized to 1 g per day of marine n-3 fatty acids or placebo (alongside vitamin D3 in a 2x2 factorial design) with a median follow-up of 5.3 years. Marine n-3 fatty acid supplementation did not significantly lower major cardiovascular events (HR, 0.92; 95% CI, 0.80 to 1.06; P=0.24) or invasive cancer (HR, 1.03; 95% CI, 0.93 to 1.13; P=0.56). For secondary endpoints, total myocardial infarction was lower in the n-3 group (HR, 0.72; 95% CI, 0.59 to 0.90), but stroke, cancer death, and all-cause death showed no significant differences. No excess risks of bleeding or other serious adverse events were observed.
Manson JE, Cook NR, Lee IM, et al. N Engl J Med, 2019. PMID 30415637
2019 / Three experimental studies (laboratory and field)
Three studies examined the effect of a justification cue (license condition) versus no cue (control condition) on caloric consumption. In Studies 1 (N = 85) and 2 (N = 95), participants could eat freely from unhealthy snacks, while in Study 3 (N = 110), participants chose a snack at a take-out lunch place. Across all studies, caloric consumption was higher in the license condition compared to the control condition, with participants eating more unhealthy snacks in Studies 1 and 2 and choosing higher-calorie snacks in Study 3.
Prinsen S, Evers C, de Ridder DTD Psychol Health, 2019. PMID 30422003
2019 / Controlled trial
In a controlled trial, 49 strict vegan participants took oral creatine monohydrate (5 g daily, n = 31) or placebo (n = 18) for three weeks. Creatine intake normalized homocysteine levels in all participants and increased blood folic acid concentrations. Supplementation also increased baseline skin capillary density and endothelium-dependent capillary recruitment, while enhancing microvascular vasodilation specifically in participants with elevated baseline homocysteine.
Van Bavel D, de Moraes R, Tibirica E Fundam Clin Pharmacol, 2019. PMID 30506745
2019 / Clinical trial
Researchers evaluated isotope-labeled l-carnitine and gamma-butyrobetaine metabolism in 40 omnivores and 32 vegans or vegetarians. Following oral d3-l-carnitine, omnivores generated over 20-fold more d3-TMAO than vegans or vegetarians (P = 0.001), despite comparable fasting plasma carnitine levels. Gut bacteria transformed carnitine into gamma-butyrobetaine in both dietary groups, but conversion of gamma-butyrobetaine to TMA was induced by chronic carnitine intake and omnivorous habits.
Koeth RA, Lam-Galvez BR, Kirsop J, et al. J Clin Invest, 2019. PMID 30530985
2019 / Controlled exposure study
Eleven healthy participants consumed about 36 g/day of commercially available palm fat containing ester-bound glycidol (8.7 mg/kg) for 4 weeks, with blood monitored over 15 weeks. Mean 2,3-diHOPr-Val adduct levels increased from 4.0 to 12.2 pmol/g hemoglobin. The mean adduct level/dose ratio was 0.082 pmol 2,3-diHOPr-Val/g hemoglobin per µg glycidol/kg body weight, and mean adduct lifetime was 104 days. Based on background levels, mean external glycidol exposure was estimated at 0.94 µg/kg body weight, which is higher than current food occurrence and consumption estimates.
Abraham K, Hielscher J, Kaufholz T, et al. Arch Toxicol, 2019. PMID 30535712
2019 / Double-blind randomized controlled trial
Older adults underwent 12 weeks of aerobic exercise training (AET) while randomized double-blind to placebo (n = 26) or metformin (n = 27). Independent of treatment, AET decreased fat mass, HbA1c, fasting plasma insulin, 24-hr ambulant mean glucose, and glycemic variability. However, metformin attenuated improvements in whole-body insulin sensitivity and VO2 max, and abrogated increases in skeletal muscle mitochondrial respiration. Mitochondrial protein synthesis rates were not different between treatments.
Konopka AR, Laurin JL, Schoenberg HM, et al. Aging Cell, 2019. PMID 30548390
2019 / Dietary intervention study
Researchers analyzed 54 omnivores who followed a lacto-ovo-vegetarian diet (VD) for 3 months as part of the CARDIVEG study. The VD led to a significant 51.2% reduction in vitamin B12 intake (P<0.001) and a significant 6.2% decrease (-24.5 pg/ml) in circulating vitamin B12 levels (P=0.005). Changes in vitamin B12 intake significantly correlated with changes in circulating levels (R 0.61, P<0.001). A reduction in vitamin B12 intake greater than -28.5% was linked to a significantly higher risk of experiencing a decrease in circulating vitamin B12 levels (OR 10.1; 95% CI 1.3, 76.1).
Dinu M, Pagliai G, Cesari F, et al. Br J Nutr, 2019. PMID 30585554
2019 / Randomized controlled trial
Fifty-six ambulatory women aged 50 or older with daily urinary incontinence were randomized to a 3-month Iyengar-based yoga program or a muscle stretching and strengthening control program; both received self-management education. Over 3 months, total incontinence frequency decreased by an average of 76% in the yoga group versus 56% in controls (P = .07). Stress incontinence frequency decreased by 61% in the yoga group compared to 35% in controls (P = .045), while changes in urgency incontinence frequency showed no significant difference between groups. High retention (89%) was observed with no adverse events directly attributable to the interventions.
Huang AJ, Chesney M, Lisha N, et al. Am J Obstet Gynecol, 2019. PMID 30595143